CML, Chronic Phase Clinical Trial
Official title:
Phase 2 Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study
To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.
To determine:
- Duration of response
- Progression free survival
- Proportion of responders 2 years after discontinuation of inecalcitol
- Duration of response after discontinuation of inecalcitol and imatinib
- Bone remodelling effect
- Safety of inecalcitol in combination with imatinib
- Quality of Life
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06409936 -
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
|
Phase 2 | |
| Recruiting |
NCT05353205 -
A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
|
Phase 4 | |
| Not yet recruiting |
NCT06121765 -
Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI
|
||
| Recruiting |
NCT03459534 -
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
|
Phase 3 | |
| Completed |
NCT03885830 -
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
|
||
| Completed |
NCT04883125 -
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT05367765 -
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
|
Phase 4 | |
| Recruiting |
NCT05367700 -
A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
|
Phase 1 |